MarketCap
Facebook
X
Telegram
ImmunoGen Income Statement 2022-2009 | IMGN
Brief overview of revenue and earnings at ImmunoGen
This overview is based on financial performance over the past five years. According to figures from ImmunoGen, revenue changed from 39.4 million dollars to 109 million dollars over five years. Across the full period, sales moved by +175.8%; the average annual rate was 22.5%. The annual growth rate indicates an exceptionally strong top-line trend.
The five-year EBITDA result moved by −5557.4%: from −$3.9 million to −$219 million. Changes in revenue did not translate into comparable EBITDA performance. At the operating-margin level, the figure shifted from −9.8% to −201.4%. Operating return per unit of revenue declined.
Net income moved from −13.1 million dollars at the start to −223 million dollars at the end. The period ended with a larger loss than it began with.
Market value was $900 million at the start and $1 billion at the end. Capitalization grew more slowly than the underlying results.
Overall conclusion
The results contain several connected negative signals. Key strengths include a larger revenue base. The most visible risks are weaker operating efficiency, lower net income and a low EBITDA margin. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement ImmunoGen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.02 B | 1.16 B | 1.26 B | 700 M | 735 M | 900 M | 204 M | 730 M | 652 M | 1.26 B | 1.1 B | 973 M | - | - |
Shares |
254 M | 206 M | 176 M | 148 M | 140 M | 98.1 M | 87.1 M | 86 M | 85.5 M | 84.1 M | 76.8 M | 68.9 M | 58.8 M | - |
Historical Prices |
4.01 | 5.65 | 7.13 | 4.72 | 5.25 | 9.18 | 2.34 | 8.49 | 7.63 | 15 | 14.3 | 14.1 | - | - |
Net Income |
-223 M | -139 M | -44.4 M | -104 M | -169 M | -13.1 M | -34.2 M | -33.2 M | 13.6 M | 3.81 M | -24.4 M | -12.8 M | -14.2 M | - |
Revenue |
109 M | 69.9 M | 132 M | 82.3 M | 53.4 M | 39.4 M | 13.8 M | 18 M | 48.3 M | 30.1 M | 2.61 M | 7.62 M | 4.18 M | - |
Gross Profit |
- | - | - | -32.3 M | -121 M | -24.3 M | -88.1 M | -26.2 M | -47.1 M | -51.5 M | 16.4 M | 19.3 M | - | - |
Operating Income |
-221 M | -125 M | -22.4 M | -92.2 M | -161 M | -9.84 M | -28.6 M | -28.2 M | 13.8 M | 3.75 M | -24.5 M | -12.8 M | -15.5 M | - |
Interest Expense |
-994 K | -1.13 M | 481 K | 590 K | -895 K | 1.46 M | -742 K | -42 K | 123 K | 72 K | -128 K | 1.7 M | 1.28 M | - |
EBITDA |
-219 M | -123 M | -20.3 M | -88.1 M | -154 M | -3.87 M | -25.6 M | -22.7 M | 18.4 M | 8.39 M | -19.9 M | -7.84 M | -10.7 M | - |
Operating Expenses |
330 M | 195 M | 155 M | 174 M | 215 M | 49.3 M | 42.5 M | 46.3 M | 34.5 M | 26.3 M | 27.1 M | 20.4 M | 19.7 M | - |
General and Administrative Expenses |
116 M | 43.8 M | 38.6 M | 38.5 M | 36.7 M | 9.05 M | 8.54 M | 8.05 M | 6.87 M | 5.45 M | 5.46 M | 4.83 M | 3.69 M | - |
All numbers in USD currency
Quarterly Income Statement ImmunoGen
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
273 M | 263 M | 259 M | 226 M | 254 M | 253 M | 253 M | 220 M | 205 M | 200 M | 199 M | 195 M | 175 M | 174 M | 167 M | 150 M | 148 M | 148 M | 148 M | 149 M | 147 M | 134 M | 131 M | 133 M | 93 M | 87.2 M | 87.2 M | 87.3 M | 87 M | 87 M | 86.8 M | 87 M | 86.1 M | 85.9 M | 85.9 M | 85.9 M | 85.7 M | 85.4 M | 85 M | 85.4 M | 84.3 M | 84.1 M | 83.4 M | 84.1 M | 77 M | 76.5 M | 76.4 M | 76.5 M | 76.4 M | 76.4 M | 68.1 M |
Net Income |
30.7 M | -4.25 M | -41 M | -59 M | -77.8 M | -62 M | -24.1 M | -37.2 M | -37.3 M | -30.7 M | -34.1 M | 31.4 M | -22.4 M | -24.3 M | -29.1 M | 4.81 M | -21.8 M | -43.4 M | -43.8 M | -41.8 M | -46.8 M | -41.6 M | -38.6 M | -13.1 M | -56.7 M | -8.87 M | -17.3 M | -34.2 M | -31.9 M | -33.2 M | -33.7 M | -33.2 M | -21.6 M | 13.6 M | -22.3 M | 13.6 M | -37.5 M | 3.81 M | -11.2 M | 3.81 M | -1.35 M | -24.4 M | -25.2 M | -24.4 M | -18.7 M | -12.8 M | -19.5 M | -12.8 M | -19.5 M | -12.8 M | -19.5 M |
Revenue |
113 M | 83.2 M | 49.9 M | - | 15.4 M | 14.2 M | 38.1 M | - | 9.21 M | 16.9 M | 15.7 M | - | 18.2 M | 15 M | 13.3 M | 44.9 M | 13.3 M | 15.5 M | 8.58 M | 13.4 M | 10.9 M | 9.29 M | 19.8 M | 39.4 M | 8.48 M | 39 M | 28.5 M | 13.8 M | 19.7 M | 18 M | 14.9 M | 18 M | 11.4 M | 48.3 M | 13.2 M | 48.3 M | 6.88 M | 30.1 M | 17.2 M | 30.1 M | 25 M | 2.61 M | 4.09 M | 2.61 M | 3.25 M | 7.62 M | 2.54 M | 7.62 M | 2.54 M | 7.62 M | 2.54 M |
Operating Income |
26 M | -4.19 M | -42.4 M | - | -77.4 M | -61.1 M | -22.9 M | - | -34.2 M | -27.4 M | -28.9 M | - | -16.7 M | -18.4 M | -23.8 M | 8.49 M | -18 M | -41.1 M | -41.6 M | -40.4 M | -45.5 M | -38.8 M | -36.7 M | -9.84 M | -31.1 M | -5.14 M | -12.9 M | -28.6 M | -27.6 M | -28.2 M | -28.6 M | -28.2 M | -21.2 M | 13.8 M | -21.9 M | 13.8 M | -37.4 M | 3.75 M | -11.3 M | 3.75 M | -1.31 M | -24.5 M | -25.2 M | -24.5 M | -18.7 M | -12.8 M | -19.5 M | -12.8 M | -19.5 M | -12.8 M | -19.5 M |
Interest Expense |
-164 K | -8 K | 63 K | - | -998 K | -480 K | -98 K | - | -365 K | 197 K | -480 K | - | 11 K | 106 K | -198 K | - | -521 K | 167 K | -71 K | - | -75 K | -1.05 M | 537 K | - | 480 K | 751 K | 134 K | - | 551 K | -4 K | -38 K | -4 K | -379 K | -146 K | -372 K | -160 K | -7 K | 62 K | 111 K | 62 K | -39 K | 115 K | 56 K | 115 K | 33 K | 23 K | -17 K | 23 K | -17 K | 23 K | -17 K |
EBITDA |
27.3 M | -3.31 M | -41.9 M | - | -76.1 M | -60.1 M | -22.4 M | - | -32.7 M | -26.3 M | -28.4 M | - | -15.2 M | -17.3 M | -23.3 M | 8.49 M | -14.7 M | -38.6 M | -40.4 M | -40.4 M | -39.3 M | -33.7 M | -34.2 M | -9.84 M | -26.8 M | -2.2 M | -11.4 M | -28.6 M | -23.8 M | -25.8 M | -27.5 M | -28.2 M | -17 M | 16.6 M | -20.5 M | 13.8 M | -34 M | 6.06 M | -10.2 M | 3.75 M | 2.2 M | -22.2 M | -24.1 M | -24.5 M | -15.2 M | -10.5 M | -18.3 M | -12.8 M | -18.3 M | -10.5 M | -18.3 M |
Operating Expenses |
87.5 M | 87.3 M | 92.3 M | - | 92.8 M | 75.2 M | 60.9 M | - | 43.4 M | 44.3 M | 44.6 M | - | 34.9 M | 33.4 M | 37.1 M | 36.4 M | 31.2 M | 56.6 M | 50.2 M | 53.8 M | 56.5 M | 48 M | 56.6 M | 49.3 M | 39.6 M | 44.2 M | 41.4 M | 42.5 M | 47.3 M | 46.3 M | 43.5 M | 46.3 M | 32.7 M | 34.5 M | 35.1 M | 34.5 M | 44.3 M | 26.3 M | 28.6 M | 26.3 M | 26.3 M | 27.1 M | 29.3 M | 27.1 M | 22 M | 20.4 M | 22 M | 20.4 M | 22 M | 20.4 M | 22 M |
General and Administrative Expenses |
37.7 M | 36.4 M | 40 M | - | 33.6 M | 23.8 M | 16.6 M | - | 10.3 M | 9.73 M | 10.2 M | - | 10.2 M | 9.77 M | 8.86 M | 9.8 M | 9.21 M | 8.7 M | 10.8 M | 9.75 M | 8.35 M | 8.65 M | 10 M | 9.05 M | 7.91 M | 8.84 M | 8.12 M | 8.54 M | 11.2 M | 8.05 M | 8.33 M | 8.05 M | 7 M | 6.87 M | 7.1 M | 6.87 M | 6.04 M | 5.45 M | 6.53 M | 5.45 M | 5 M | 5.46 M | 5.64 M | 5.46 M | 5.02 M | 4.83 M | 4.84 M | 4.83 M | 4.84 M | 4.83 M | 4.84 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company ImmunoGen (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
